Specialty Chemical Stock Sudarshan Pharma Confirms Fundraising Up to Rs 1500 Cr; Incorporates Subsidiary In US

Due to its recent move to raise Rs 1,500 crore through the offering of equity shares through a public issue, qualified institutions placement, or private placement at a face value of Rs 1 each, Sudarshan Pharma Industries, a small cap company in the specialty chemical industry, has drawn the attention of market watchers.

"This is to inform you that the Board of Directors of the Company at its Board meeting held today, i.e. 19th June, 2025 has approved the proposal to raising of funds by way of issuance of equity shares and/or eligible securities (convertible/non- convertible) through permissible modes in one or more tranches, in the course of domestic and/or international offering(s) in one or more foreign markets, by way of a public issue, preferential issue, qualified institutions placement, private placement or a combination thereof of equity shares of the Company having face value of Re.1 (Rupee One only) each or through an issuance of Global Depository Receipts, Foreign Currency Convertible Bonds, fully convertible debentures / partly convertible debentures / non-convertible debentures with warrants, with a right exercisable by the warrant holder to exchange the said warrants with Equity Shares / any other securities (other than warrants), which are convertible into or exchangeable with Equity Shares, whether rupee denominated or denominated in foreign currency for an amount not exceeding to Rs.1500 Crores or equivalent amount in foreign currency, in one or more tranches, subject to the approval of regulatory statutory authorities and the members of the Company at a general meeting," said Sudarshan Pharma in a regulatory filing.

Along with the aforementioned fundraising strategy, Sudarshan Pharma Industries has also announced the establishment of a wholly owned subsidiary in the United States of America under the proposed name "Sudarshan Industries LLC" or any other name that may be authorized by US authorities. Furthermore, on Thursday, the company's Board of Directors authorized the incorporation of a wholly-owned subsidiary company in Canada, which would function as a subsidiary of the company.

The Board of Directors of Sudarshan Pharma Industries has approved the acquisition of land, building, plant, and machinery totaling 1,563.15 square meters, located at Plot nos. D-22, IDA-Medchal, Medchal Mandal, Malkajigiri District, Telangana, PIN 501401, for a total sale consideration of Rs. 25.50 Crores from Srigen Lifesciences Private Limited.

An Indian business called Sudarshan Pharma Industries Limited is mainly involved in the production and distribution of chemicals and solvents, with an emphasis on specialty chemicals and intermediates for a range of industries. In addition, the company is engaged in contract manufacturing of generic pharmaceutical formulations and medications and produces active pharmaceutical ingredients (APIs).